Takeaway
- A small real-world study provides insight into the relative efficacy of secukinumab (Cosentyx) vs ustekinumab (Stelara) in patients with moderate to severe psoriasis.
Why this matters
- Several biologic treatments are now available for psoriasis, which necessitates comparative studies in regular clinical practice.
Key results
- At week 52, patients treated with secukinumab were more likely to achieve ≥90% improvement in the Psoriasis Area and Severity Index (PASI 90) compared with patients treated with ustekinumab (82.75% vs 43.33%; P=.002).
- PASI75 response was not statistically different between groups (89.65% vs 73.33%,P=.108).
- The most common adverse events were upper respiratory tract infections (6.9% for secukinumab, 6.7% for ustekinumab) and headache of low/mild severity (6.9% for secukinumab, 10% for ustekinumab).
Study design
- 59 patients with psoriasis, 29 treated with secukinumab and 30 with ustekinumab, were analyzed for skin clearance.
- Funding: None disclosed.
Limitations
- Small patient sample size.
- Retrospective study.
References
References
